Information pooled in a meta-analysis of 18 data sets may allow clinicians to fine-tune the ultrasonographic surveillance of small abdominal aortic aneurysms, according to a report in the Feb. 27 issue of JAMA.
"Currently, there is no consensus regarding appropriate surveillance intervals for patients with (AAAs) [abdominal aortic aneurysms]. By pooling results from 18 studies, we quantified AAA growth rates and the AAA rupture risk as a function of aortic diameter. Our intent was to provide an objective basis for selecting surveillance intervals for patients with small AAAs," said Simon G. Thompson, D.Sc., of the cardiovascular epidemiology unit, department of public health and primary care, University of Cambridge (England), and his associates.
Their findings suggest that the overall number and frequency of surveillance scans can be reduced, at least for men. However, the picture is still unclear for women, and more research is required before specific recommendations can be made, the investigators said.
Dr. Thompson and his colleagues reviewed randomized trials, observational studies, and papers presented at vascular surgical conferences that included data sets with 100 or more patients who underwent repeated ultrasound measurements of the diameter of AAAs over time. This yielded 18 data sets that included 15,471 subjects with AAA diameters between 3.0 and 5.4 cm, because 5.5 cm is usually the threshold at which surgical repair of the lesion is recommended.
The 13,728 men and 1,743 women were followed for an average of 1-8 years. There were "relatively few" AAA ruptures: 178 among men and 50 among women.
Among men, a 3-cm AAA took a mean of 7.4 years to have a 10% chance of reaching 5.5 cm, a 4-cm AAA took a mean of 3.2 years to have a 10% chance of reaching 5.5 cm, and a 5-cm AAA took a mean of 0.7 years to have a 10% chance of reaching 5.5 cm.
Similarly, rupture rates among men approximately doubled for every 0.5-cm increase in AAA diameter. For AAAs with diameters of 3.0-4.5 cm, the average time to reach a rupture risk of 1% was at least 2 years.
These data can be used to guide the decision of how often to perform ultrasound surveillance of AAAs in men. Based on the lower 95% confidence limits, the risk of rupture in men would be less than 1% if surveillance intervals were extended to 3 years for AAAs measuring 3.0-3.9 cm, to 2 years for those measuring 4.0-4.4 cm, and to 1 year for those measuring 4.5-5.4 cm.
"For a U.S. patient with a 3.0-cm AAA detected by screening, this would reduce the average number of surveillance scans from approximately 15 to 7," the investigators wrote (JAMA 2013;309:806-13).
However, if the lower 95% prediction limits of the estimates were applied (to acknowledge that the population in each study might have different growth and rupture rates), the risk of rupture in men would be less than 1% if surveillance intervals were extended to 2 years for AAAs measuring 3.0-3.9 cm, to 1 year for those measuring 4.0-4.9 cm, and to 6 months for those measuring 5.0-5.4 cm. This would result in a lesser average reduction in the number of surveillance scans from 15 to 10.
The rate of rupture was four times higher for women than for men, even though the rate of AAA growth was similar. The higher risk of AAA rupture in women is well known, although the reasons for this discrepancy are not yet certain. Researchers have proposed that differences in anatomy, structure, sex hormones, and smoking habits all may play a role.
"The clinical implication is that a lower AAA diameter threshold for surgery should be adopted for women, a recommendation already made by the joint council of the American Association for Vascular Surgery and the Society for Vascular Surgery," Dr. Thompson and his associates wrote.
A threshold of 4.5 cm rather than 5.5 cm might be more appropriate for women, but this decision must be weighed against the evidence that women have a higher operative mortality than men and a poorer outcome at postoperative hospital discharge, the investigators noted.
This study was supported by the U.K. National Institute for Health Research’s Health Technology Assessment Programme. The authors reported that they had no relevant financial conflicts, although individual members had participated in aneurysm clinical trials.